Diabetes

Inhaled insulin stymied by drive for value

Inhaled insulin stymied by drive for value

By

Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.

Five things for pharma marketers to know: Monday, May 18

Five things for pharma marketers to know: Monday, May 18

By

Endo agrees to buy Par Pharmaceuticals for $8 billion; AstraZeneca deepens commitment to biologics; FDA cautions that certain diabetes drugs could lead to serious condition

Diabetes advocate Manny Hernandez joins digital health firm

Hernandez is known for his ability to bring together patients and pharma. He joined Livongo Health to aid the firm's user experience.

Five things for pharma marketers to know: Thursday, April 30

Five things for pharma marketers to know: Thursday, April 30

By

FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins

Five things for pharma marketers to know: Tuesday, April 28

Five things for pharma marketers to know: Tuesday, April 28

By

Merck said Januvia is not linked to higher heart-failure risk; Biogen plans to spend $2.5 billion on Alzheimer's disease; Mylan rejected Teva's bid

Lilly sees sales fall but reaffirms 2015 revenue guidance

Lilly sees sales fall but reaffirms 2015 revenue guidance

By

First-quarter sales fell 1% but the drugmaker expects 2015 to be a growth year.

FDA committee recommends label change for Onglyza

FDA committee recommends label change for Onglyza

By

Despite an FDA committee voting that AstraZeneca's diabetes medication carries an acceptable heart risk, analysts say a Merck study will determine the DPP-IV category's fate.

Five things for pharma marketers to know: Wednesday, April 15

Five things for pharma marketers to know: Wednesday, April 15

By

An FDA panel said heart risks should be part of Onglyza's label; the OIG will examine generic price increases; Abbott said its OTC glucose meter will save patients money

Five things for pharma marketers to know: Monday, April 13

Five things for pharma marketers to know: Monday, April 13

By

Sanofi won't discount new insulin; Takeda appoints new US business head; insurers push back on expensive preventative genetic tests

Five things for pharma marketers to know: Friday, April 10

Five things for pharma marketers to know: Friday, April 10

By

AstraZeneca diabetes drug may have increased mortality rate; Pfizer accused of knowing about birth defect risks from Zoloft; Eisai to cut 25% of its US workforce

FDA Onglyza panel review set for Tuesday

FDA Onglyza panel review set for Tuesday

By

The panel will focus on heart failure hospitalization rates associated with the diabetes medication.

Five things for pharma marketers to know: Wednesday, April 1

Five things for pharma marketers to know: Wednesday, April 1

By

Takeda proposes $2.2-billion settlement to resolve Actos suits; Public Citizen says diabetes drugs are unlawfully promoted; PAIN study says 20% to 30% of opioid drugs are misused

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

By

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Five things for pharma marketers to know: Thursday, March 19

Five things for pharma marketers to know: Thursday, March 19

By

A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research

US pharma market value projected to be $550 billion in five years

US pharma market value projected to be $550 billion in five years

By

Oncology and diabetes medications are expected to be major areas of growth.

Medtronic teams up with Glooko

The diabetes device manufacturer will soon work with Glooko's platform.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

By

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

AstraZeneca, Joslin Diabetes Center ink three-year collaboration

The partners will focus on developing treatments for metabolic disorders.

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

By

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Sanofi's new Lantus may not be the new Lantus

Sanofi's new Lantus may not be the new Lantus

By

Potential patients are expected to be newly diagnosed diabetes patients as opposed to Lantus switchers.

Lilly Lantus biosimilar to hit EU

The EU will have access to the new medication in May.

Lilly peglispro delay may be boon for its biosimilar

Lilly peglispro delay may be boon for its biosimilar

By

The drugmaker wants to put the drug through additional liver-impact tests.

Study shows Lucentis at Eylea disadvantage

Study shows Lucentis at Eylea disadvantage

By

An NIH study shows possible limit to Lucentis's appeal.

Merck Januvia survey sparks ethics debate

A Merck survey that indicated distaste for British Columbia's decision to boot Januvia from the formulary has stirred up debate over bias.

Five things for pharma marketers to know: Monday, February 9

Five things for pharma marketers to know: Monday, February 9

By

Achillion's experimental HCV drug cleared the virus in six weeks when combined with Gilead's Sovaldi; Sanofi will replace a third of its sales managers; GSK shutters Montana vaccine R&D.

CDC: diabetes patient costs have doubled

The reason: higher prices and more services.

Lilly expands Trulicity marketing push, lowers 2015 guidance

Lilly expands Trulicity marketing push, lowers 2015 guidance

By

The drugmaker says its Trulicity focus now includes primary care doctors in addition to specialists, and that foreign exchange will take a bite out of 2015 performance.

Five things for pharma marketers to know: Wednesday, January 28

Five things for pharma marketers to know: Wednesday, January 28

By By

Doximity professional network now includes financial data; Pfizer settles class-action lawsuit; researchers hope to use temporary tattoos to identify glucose levels.

Five things for pharma marketers to  know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

By By By

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Novo seeks to make Saxenda a familiar name in weight loss

Novo seeks to make Saxenda a familiar name in weight loss

By

The company is set to introduce its newest brand, Saxenda, into the crowded prescription obesity market as a higher-dose form of liraglutide than diabetes shot Victoza.


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters